Featured Courses

Effective Management of Psoriasis and Psoriatic Arthritis

1.50 AMA PRA Category 1 Credit(s)™

In the first interactive MediTalk digital roundtable discussion in the series, the expert faculty will review the safety, efficacy, and limitations of the currently available therapies for managing patients with psoriasis and/or psoriatic arthritis (PsA).

Primary Care Strategies for the Management of Common Urological Disorders in Men
1.00 AMA PRA Category 1 Credit(s)™

Lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH), frequently referred to as LUTS/BPH, is a common urological disorder in men that negatively impacts their quality of life. Primary care management of LUTS/BPH begins...

Emerging Science and Therapies in Non-small Cell Lung Cancer: Targeting the MET Pathway

2.00 AMA PRA Category 1 Credit(s)™

Over the past decade, research has evolved in the science of identifying targeted biological changes in DNA and individual cancer cells. Along with the advanced understanding of lung cancer mutations...

Strategies to Improve Outcomes in Patients with Overactive Bladder
2.00 AMA PRA Category 1 Credit(s)™

Overactive bladder is a unique, symptom-based condition within the field of urology. Recently, the American Urological Association (AUA) released assessment and treatment recommendations for overactive bladder.

Despite the availability of a number of therapeutic options, management of type 2 diabetes (T2DM) and hyperglycemia remains suboptimal. Evidence shows that physicians are not adequately individualizing incretin-based therapies as there is lack of clear understanding of the similarities and differences between various incretin-based therapies....
Systemic lupus erythematosus (SLE) is a chronic, relapsing autoimmune disease of the connective tissues, primarily affecting the skin, kidneys, heart, lungs, nervous system, blood, and joints. SLE is characterized by cytokine dysregulation, polyclonal B-cell activation, autoantibody production, and increased immune complex formation due to...
Recent studies have changed the landscape and thinking on anticoagulation management and stroke prevention in patients with cardiac disease. Therapeutic options now include agents with unique modes of action and exciting new data on patient outcomes. This CME initiative will educate healthcare providers on the current applications of oral...
With the advent of JAK2 inhibitors, viable, clinically important treatment options are now becoming available and there is a clear need for focused educational efforts on the diagnosis and prognostic risk-based treatment approaches to myelofibrosis. This unique webcast will be led and developed by a panel of expert physicians who specialize in...
The management of patients with rheumatoid arthritis actively evolves as further evidence-based data becomes available. The relatively recent development of biologics and DMARDS has presented new challenges in clinical decision making for the busy rheumatologist. This program is designed to provide a review of immunology science which is necessary...
This Medical Meeting Reporter will present and summarize important presentations and abstracts from the 66th Annual Meeting of the American Academy of Neurologists (AAN). AAN is the world’s largest professional association of neurologists with over 26,000 members and strives to promote the highest caliber patient-centered neurologic care....
Given the rapidly evolving field of cardiac stress testing with respect to new risk stratification algorithms, new agents, and new assessment methods, it is difficult for physicians to remain up to date on the latest research and the benefits and risks of different testing modalities. This CME activity provides an overview on the indications and...
The American Epilepsy Society Annual Meeting (AES 2013) scientific sessions presented longer-term analysis of current available therapies as well as the emerging science of therapies in development. In particular, much of the evidence-based medicine addressed the unmet need of treatment resistant epilepsy. This CME activity is a synopsis of the...
The pathobiology of myelofibrosis continues to advance and the current understanding of myelofibrosis is complex. Guidelines and recommendations for the diagnosis of myelofibrosis, including the revised WHO criteria for myelofibrosis, is controversial. The clinical trial data on JAK2 inhibitor therapeutics has changed the clinical approach to...
Emerging Developments in Hepatitis C Virus Treatment
1.00
  • AMA PRA Category 1 Credit(s)™
The 64th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) 2013 was very dynamic during this exciting era of newer pharmacotherapies to manage patients with hepatitis C. Nancy Reau, MD has reviewed and selected the major clinical trial data presented at AASLD 2013 to develop this comprehensive...
Improving Patient Outcomes In Multiple Sclerosis: Clinical Trial Data and Management Strategies
2.00 AMA PRA Category 1 Credit(s)™

The ArcheMedX learning architecture offers participants interaction to achieve a deeper understanding of the content allowing the learner opportunities to sharpen their clinical skills.

Controversies in the Treatment of Male Hypogonadism
1.00 AMA PRA Category 1 Credit(s)™

This CME program provides urologists and other healthcare providers an awareness of the various conflicting definitions of hypogonadism, screening guidelines, and the clinical data supporting the benefits and relative safety of testosterone replacement therapy.